DA Davidson analyst Linda Weiser lowered her price target on Nu Skin to $35 after its in-line Q4 EPS and the 28% decline in its constant currency sales in China. The analyst notes that the company has suspended meetings in that market due to the coronavirus outbreak, driving its "big" expected 2020 earnings declines with no growth until Q4. Weiser adds that while Nu Skin's free cash flow may be below dividends, a payout cut is "highly unlikely" as she lowers the target valuation on the stock to 5.5-times from 6.0-times enterprise value to expected EBITDA.